<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05101135</url>
  </required_header>
  <id_info>
    <org_study_id>JLP-2008-301</org_study_id>
    <nct_id>NCT05101135</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin</brief_title>
  <official_title>This Study Evaluates the Addition of Dapagliflozin in the Treatment of Type 2 Diates With Metformin and JT-001 Combination Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeil Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jeil Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the&#xD;
      Efficacy and Safety of JT-001 Add-on in Patients with Type 2 Diabetes Mellitus Inadequately&#xD;
      Controlled with Metformin and Dapagliflozin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 8, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in HbA1c</measure>
    <time_frame>24th Week</time_frame>
    <description>Changes in HbA1c at the 24th week from the baseline</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>JT-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: JT-001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JT-001 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: JT-001 Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JT-001</intervention_name>
    <description>Subjects take the investigational products once a day for 24 weeks.</description>
    <arm_group_label>JT-001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JT-001 Placebo</intervention_name>
    <description>Subjects take the investigational products once a day for 24 weeks.</description>
    <arm_group_label>JT-001 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults aged 19 years or older with type 2 diabetes mellitus&#xD;
&#xD;
          2. Subjects with 7.0% ≤ HbA1c ≤ 11% at baseline&#xD;
&#xD;
          3. Those with &gt; 45 kg/m2 of BMI&#xD;
&#xD;
          4. Those who voluntarily signed the informed consent to participate in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who had allergic reaction to main ingredients or components of the&#xD;
             investigational products.&#xD;
&#xD;
          2. Patients with the following major systemic disease&#xD;
&#xD;
               -  Patients with type 1 diabetes mellitus, secondary diabetes, or congenital renal&#xD;
                  diabetes etc.)&#xD;
&#xD;
               -  Patients with pituitary insufficiency or adrenal dysfunction&#xD;
&#xD;
               -  Patients with uncontrolled glycosemia(FPG &gt; 270 mg/dL)&#xD;
&#xD;
               -  Patients with uncontrolled hypertension(SBP &gt; 180 mmHg or DBP &gt; 110 mmHg&#xD;
&#xD;
               -  Patients with severe hypertriglyceridemia (Triglyceride &gt; 500 mg/dL)&#xD;
&#xD;
               -  Patients with severe renal dysfunction&#xD;
&#xD;
               -  Patients with liver dysfunction&#xD;
&#xD;
               -  Patients with AIDS&#xD;
&#xD;
               -  Those with clinically significant severe infection or trauma based on an&#xD;
                  investigator's judgement&#xD;
&#xD;
               -  Patients with pulmonary infarction, severe pulmonary dysfunction, hypoxemia&#xD;
&#xD;
               -  Unstable mental illness not regulated by drugs&#xD;
&#xD;
               -  Those who suffered from gastrointestinal diseases that may affect the absorption,&#xD;
                  distribution, metabolism, and excretion of investigational products or had&#xD;
                  underwent surgery;&#xD;
&#xD;
               -  Those who had genetic disorders such as galactose intolerance, Lapp lactose&#xD;
                  deficiency, or glucose-galactose malabsorption&#xD;
&#xD;
          3. Those with a history of malignant tumor within 5 years&#xD;
&#xD;
          4. Those with history of alcohol or drug abuse within 1 years&#xD;
&#xD;
          5. Those with heart failure (NYHA class II~IV) or who had suffered from heart failure&#xD;
             within 6 months&#xD;
&#xD;
          6. Those who underwent surgery requiring general anesthesia within 4 weeks as of Visit 1&#xD;
             or who are scheduled to receive such surgery within 4 weeks after the study ends&#xD;
&#xD;
          7. Those who need to take prohibited concomitant medications stated during the study&#xD;
             period.&#xD;
&#xD;
          8. Females who are pregnant or breastfeeding or patients planning to become pregnant or&#xD;
             of childbearing potential, but not using any recognized contraceptive method&#xD;
&#xD;
          9. Those who are judged unsuitable for the study by a principal investigator or&#xD;
             investigators&#xD;
&#xD;
         10. Those who have been administered with the following drugs or expected to require the&#xD;
             continued administration during the study period:&#xD;
&#xD;
               -  Those who have been administered with obesity drugs within 12 weeks&#xD;
&#xD;
               -  Those being administered with thyroid medications and whose dose has been&#xD;
                  modified within 6 weeks&#xD;
&#xD;
               -  Those administered with systemic steroid agents (Prednisolone, &gt;30 mg/day) within&#xD;
                  2 weeks&#xD;
&#xD;
               -  Those being administered with diuretics and whose dose has been modified within 8&#xD;
                  weeks as (however, dose reduction is accepted.)&#xD;
&#xD;
         11. Those who are currently participating in other ongoing clinical studies or those who&#xD;
             have taken the investigational products from other clinical studies within 12 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bong-Soo Cha, MD., Ph.D</last_name>
    <phone>+82-2-2228-1962</phone>
    <email>BSCHA@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bong-Soo Cha, M.D. Ph.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 19, 2021</study_first_submitted>
  <study_first_submitted_qc>October 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

